Skip to content
Disclosery

Euclidean Capital LLC

Follow

13F filer, CIK 1825034, NEW YORK, NY

Euclidean Capital LLC reported $369,450,641 across 12 holdings for the quarter ended 2025-12-31, in a 13F-HR filed 2026-02-17. Its ten largest share positions make up 99.8% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001012975-26-000154

Period
2025-12-31
Reported value
$369M
Holdings
12
Top 10 weight
99.8%
New
1
Sold out
0

Largest buys vs the previous quarter

SecurityShares changeApprox. value
VTVnew+520,000$99.3M
VEUadded+411,900$30.3M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

None.

Holdings, Q4 2025

Share positions as resolved from 13F-HR 0001012975-26-000154, largest first. % of portfolio is the value over $369,450,641, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
VEUVANGUARD INTL EQUITY INDEX FQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 507,600 shares; 2024Q4: 1,013,434 shares; 2025Q1: 1,991,884 shares; 2025Q2: 2,142,684 shares; 2025Q3: 2,578,184 shares; 2025Q4: 2,990,084 shares 2,990,084$220M59.53%+411,900Timeline
VTVVANGUARD INDEX FDSQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 520,000 shares 520,000$99.3M26.88%newTimeline
INDAISHARES TRQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 2,425,144 shares; 2024Q4: 2,425,144 shares; 2025Q1: 2,425,144 shares; 2025Q2: 2,425,144 shares; 2025Q3: 369,600 shares; 2025Q4: 369,600 shares 369,600$20M5.41%0Timeline
FHTXFOGHORN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,573,761 shares; 2024Q4: 1,573,761 shares; 2025Q1: 1,573,761 shares; 2025Q2: 1,573,761 shares; 2025Q3: 1,573,761 shares; 2025Q4: 1,573,761 shares 1,573,761$8.5M2.3%0Timeline
ORICORIC PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 989,410 shares; 2024Q4: 989,410 shares; 2025Q1: 989,410 shares; 2025Q2: 989,410 shares; 2025Q3: 989,410 shares; 2025Q4: 989,410 shares 989,410$8.09M2.19%0Timeline
PMVPPMV PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 2,627,643 shares; 2024Q4: 2,627,643 shares; 2025Q1: 2,627,643 shares; 2025Q2: 2,627,643 shares; 2025Q3: 2,627,643 shares; 2025Q4: 2,627,643 shares 2,627,643$3.28M0.89%0Timeline
SPYSTATE STR SPDR S&P 500 ETF TQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,202,804 shares; 2024Q4: 896,254 shares; 2025Q1: 4,104 shares; 2025Q2: 4,104 shares; 2025Q3: 4,104 shares; 2025Q4: 4,104 shares 4,104$2.8M0.76%0Timeline
RAPTRAPT THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 82,234 shares; 2025Q3: 82,234 shares; 2025Q4: 82,234 shares 82,234$2.79M0.75%0Timeline
ALECALECTOR INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,307,858 shares; 2024Q4: 1,307,858 shares; 2025Q1: 1,307,858 shares; 2025Q2: 1,307,858 shares; 2025Q3: 1,307,858 shares; 2025Q4: 1,307,858 shares 1,307,858$2.04M0.55%0Timeline
SRZNSURROZEN INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 87,696 shares; 2024Q4: 87,696 shares; 2025Q1: 87,696 shares; 2025Q2: 87,696 shares; 2025Q3: 87,696 shares; 2025Q4: 87,696 shares 87,696$1.98M0.54%0Timeline
TNYATENAYA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,015,705 shares; 2024Q4: 1,015,705 shares; 2025Q1: 1,015,705 shares; 2025Q2: 1,015,705 shares; 2025Q3: 1,015,705 shares; 2025Q4: 1,015,705 shares 1,015,705$723K0.2%0Timeline
SRZNWSURROZEN INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 170,833 shares; 2024Q4: 170,833 shares; 2025Q1: 170,833 shares; 2025Q2: 170,833 shares; 2025Q3: 170,833 shares; 2025Q4: 170,833 shares 170,833$3.42K<0.01%0Timeline

How Q4 2025 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001012975-26-000154 base2026-02-17acceptance time not in the bulk data set